Charles River Laboratories International
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Charles River Laboratories International's revenues will expand 3.0% and EPS will grow 1.4%.
The average estimate for revenue is $294.5 million. On the bottom line, the average EPS estimate is $0.71.
Last quarter, Charles River Laboratories International reported revenue of $280.1 million. GAAP reported sales were 3.7% lower than the prior-year quarter's $291.0 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $0.64. GAAP EPS of $0.38 for Q4 were 31% lower than the prior-year quarter's $0.55 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 33.9%, 90 basis points worse than the prior-year quarter. Operating margin was 15.4%, 140 basis points worse than the prior-year quarter. Net margin was 6.6%, 270 basis points worse than the prior-year quarter.
The full year's average estimate for revenue is $1.18 billion. The average EPS estimate is $2.85.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Charles River Laboratories International is hold, with an average price target of $42.04.
Looking for alternatives to Charles River Laboratories International? It takes more than great companies to build a fortune for the future. Learn the basic financial habits of millionaires next door and get focused stock ideas in our free report, "3 Stocks That Will Help You Retire Rich." Click here for instant access to this free report.
- Add Charles River Laboratories International to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.